Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

2.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.4K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

5.1K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender, violence, and killing: Revisiting femicide, and the overlooked realities of male victimization.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same author

IVF in endometriosis: emerging evidence of exacerbation of pelvic pain and potential predictors.

Human reproduction open·2026
Same author

Estrobolome: Is there a missing link?

The Journal of steroid biochemistry and molecular biology·2026
Same author

John J. Sciarra: a life spent to foster women's health and rights.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2025
Same author

Induced abortion in the world: 3. In search of a minimum common ground.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2025
Same author

Induced abortion in the world: 2. Present views on pregnancy termination.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2025

Related Experiment Video

Updated: Apr 30, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K

Selective progesterone receptor modulators: an update.

Giuseppe Benagiano1, Carlo Bastianelli, Manuela Farris

  • 1University of Rome, 'Sapienza', Department of Gynaecology, Obstetrics and Urology , C/O AIED Via Toscana 30, 00187 Rome , Italy Manuela.farris@uniroma1.it.

Expert Opinion on Pharmacotherapy
|May 3, 2014
PubMed
Summary
This summary is machine-generated.

Selective progesterone receptor modulators (SPRMs) are highly effective for emergency contraception (EC) and preoperative treatment of uterine fibroids. Research highlights their role in reproductive medicine advancements.

Keywords:
adenomyosisasoprisnilcontraceptionemergency contraceptionendometriosismifepristoneproellexselective progesterone receptor modulatorsulipristal acetateuterine leiomyomas

More Related Videos

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

1.9K
Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

2.5K

Related Experiment Videos

Last Updated: Apr 30, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K
Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

1.9K
Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

2.5K

Area of Science:

  • Reproductive Medicine
  • Pharmacology

Background:

  • Selective progesterone receptor modulators (SPRMs) have demonstrated potential in various medical applications.
  • Previous reviews summarized SPRM research up to 2008.

Purpose of the Study:

  • To review recent advancements in reproductive medicine concerning SPRMs.
  • To highlight the clinical utility of SPRMs in emergency contraception, contraception, and preoperative management of uterine leiomyomas.

Main Methods:

  • Literature review of developments in reproductive medicine since 2008.
  • Analysis of clinical data on SPRMs, including mifepristone (MFP) and ulipristal acetate (UPA).

Main Results:

  • Mifepristone (MFP) and ulipristal acetate (UPA) are clinically used SPRMs for emergency contraception (EC).
  • MFP (10 mg) is more effective than levonorgestrel (LNG) for EC up to 120 hours.
  • UPA shows comparable efficacy to LNG for EC up to 72 hours.
  • SPRMs show promise in contraception and preoperative treatment of uterine leiomyomas, reducing size and bleeding, though endometrial changes are noted.

Conclusions:

  • Selective progesterone receptor modulators (SPRMs) are effective for emergency contraception.
  • SPRMs are beneficial for the preoperative treatment of uterine leiomyomas.